Comparison of anti-angiogenic properties of pristine carbon nanoparticles

Nanoscale Research Letters

Volumn 8, Issue 1, 2013, Pages 1-8

  Wierzbicki, Mateusz ^a   Sawosz, Ewa ^a   Grodzik, Marta ^a   Prasek, Marta ^a   Jaworski, Slawomir ^a   Chwalibog, André ^b  

^a WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Angiogenesis; Carbon nanoparticles; Diamond; Fullerene; Graphene; Graphite; Nanotubes

Indexed keywords

BIOACTIVITY; BLOOD; BLOOD VESSELS; DIAMONDS; FULLERENES; GRAPHENE; GRAPHITE; NANOPARTICLES; NANOTUBES; TUMORS;

ANGIOGENESIS; ANGIOGENIC GROWTH FACTORS; ANTI-ANGIOGENIC THERAPY; CARBON NANO-MATERIALS; CARBON NANO-PARTICLES; CHORIO-ALLANTOIC MEMBRANES; DIAMOND NANO-PARTICLES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR;

MULTIWALLED CARBON NANOTUBES (MWCN);

SPONDIAS PURPUREA;

EID: 84878762944     PISSN: 19317573     EISSN: 1556276X     Source Type: Journal    
DOI: 10.1186/1556-276X-8-195     Document Type: Article

References (46)

1. Adams RH, Alitalo K: Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007, 8:464-478.
2. Kurz H, Burri PH, Djonov VG: Angiogenesis and vascular remodeling by intussusception: from form to function. News Physiol Sci 2003, 18:65-70.
3. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
4. Shibuya M: Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006, 39:469-478.
5. Cross M, Claesson-Welsh L: FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001, 22:201-207.
6. Jain RK, Duda DG, Clark JW, Loeffler JS: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006, 3:24-40.
7. Carmeliet P, Jain RK: Molecular mechanism and clinical applications of angiogenesis. Nature 2011, 473:298-307.
8. Sayes CM, Fortner JD, Guo W, Lyon D, Boyd AM, Ausman KD, Tao YJ, Sitharaman B, Wilson LJ, Hughes JB, West JL, Colvin VL: The differential cytotoxicity of water-soluble fullerenes. Nano Lett 2004, 4:1881-1887.
9. Dumortier H, Lacotte S, Pastorin G, Marega R, Wu W, Bonifazi D, Briand JP, Prato M, Muller S, Bianco A: Functionalized carbon nanotubes are noncytotoxic and preserve the functionality of primary immune cells. Nano Lett 2006, 6:1522-1528.
10. Schrand AM, Dai L, Schlager JJ, Hussain SM, Osawa E: Differential biocompatibility of carbon nanotubes and nanodiamonds. Diam Relat Mater 2007, 16:2118-2123.
11. Liu KK, Cheng CL, Chang CC, Chao JI: Biocompatible and detectable carboxylated nanodiamond on human cell. Nanotechnology 2007, 18:325102.
12. Grodzik M, Sawosz E, Wierzbicki M, Orlowski P, Hotowy A, Niemiec T, Szmidt M, Mitura K, Chwalibog A: Nanoparticles of carbon allotropes inhibit glioblastoma multiforme angiogenesis in ovo. Int J Nanomedicine 2011, 6:3041-3048.
13. Holt KB, Ziegler C, Caruana DJ, Zang J, Millán-Barrios EJ, Hu J, Foord JS: Redox properties of undoped 5 nm diamond nanoparticles. Phys Chem Chem Phys 2008, 10:303-310.
14. Krueger A, Stegk J, Liang Y, Lu L, Jarre G: Biotinylated nanodiamond: simple and efficient functionalization of detonation diamond. Langmuir 2008, 24:4200-4204.
15. O'brien RW, Ward DN: Electrophoresis of a spheroid with a thin double layer. J Colloid Interface Sci 1988, 121:402-413.
16. Cheng XK, Kan AT, Tomson MB: Naphthalene adsorption and desorption from aqueous C60 fullerene. J Chem Eng Data 2004, 49:675-683.
17. Brooks PC, Montgomery AM, Cheresh DA: Use of the 10-day-old chick embryo model for studying angiogenesis. Methods Mol Biol 1999, 129:257-269.
18. Blacher S, Devy L, Hlushchuk R, Larger E, Lamandé N, Burri P, Corvol P, Djonov V, Foidart JM, Noël A: Quantification of angiogenesis in the chicken chorioallantoic membrane (CAM). Image Analysis & Stereology 2005, 24:169-180.
19. Ribatti D, Vacca A, Roncali L, Dammacco F: The chick embryo chorioallantoic membrane as a model for in vivo research on angiogenesis. Int J Dev Biol 1996, 40:1189-1197.
20. Flamme I: Is extraembryonic angiogenesis in the chick embryo controlled by the endoderm? A morphology study. Anat Embryol (Berl) 1989, 180:259-272.
21. Javerzat S, Franco M, Herbert J, Platonova N, Peille AL, Pantesco V, De Vos J, Assou S, Bicknell R, Bikfalvi A, Hagedorn M: Correlating global gene regulation to angiogenesis in the developing chick extra-embryonic vascular system. PLoS One 2009, 4:e7856.
22. Bakowicz-Mitura K, Bartosz G, Mitura S: Influence of diamond powder particles on human gene expression. Surf Coatings Technol 2007, 201:6131-6135.
23. Bhattacharya E, Mukherjee P, Xiong Z, Atala A, Soker S, Mukhopadhyay D: Gold nanoparticles inhibit VEGF165-induced proliferation of HUVEC cells. Nano Lett 2004, 4:2479-2481.
24. Mukherjee P, Bhattacharya R, Wang P, Wang L, Basu S, Nagy JA, Atala A, Mukhopadhyay D, Soker S: Antiangiogenic properties of gold nanoparticles. Clin Cancer Res 2005, 11:3530-3534.
25. Wang K, Ruan J, Song H, Zhang J, Wo Y, Guo S, Cui D: Biocompatibility of graphene oxide. Nanoscale Res Lett 2011, 6:8.
26. Liao KH, Lin Y, Macosko CW, Haynes CL: Cytotoxicity of graphene oxide and graphene in human erythrocytes and skin fibroblasts. ACS Appl Mater Interfaces 2011, 3:2607-2615.
27. Jiang Q, Li JC, Wilde G: The size dependence of the diamond-graphite transition. J Phys Condens Matter 2000, 12:5623.
28. Wang J, Morita I, Onodera M, Murota SI: Induction of KDR expression in bovine arterial endothelial cells by thrombin: involvement of nitric oxide. J Cell Physiol 2002, 190:238-250.
29. Duval M, Bédard-Goulet S, Delisle C, Gratton JP: Vascular endothelial growth factor-dependent down-regulation of Flk-1/KDR involves Cblmediated ubiquitination. Consequences on nitric oxide production from endothelial cells. J Biol Chem 2003, 278:20091-20097.
30. Waltenberger J, Mayr U, Pentz S, Hombach V: Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. Circulation 1996, 94:1647-1654.
31. Detmar M, Brown LF, Berse B, Jackman RW, Elicker BM, Dvorak HF, Claffey KP: Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin. J Invest Dermatol 1997, 108:263-268.
32. Olszewska-Pazdrak B, Hein TW, Olszewska P, Carney DH: Chronic hypoxia attenuates VEGF signaling and angiogenic responses by downregulation of KDR in human endothelial cells. Am J Physiol Cell Physiol 2009, 296:C1162-C1170.
33. Murugesan S, Mousa SA, O'connor LJ, Lincoln DW 2nd, Linhardt RJ: Carbon inhibits vascular endothelial growth factor- and fibroblast growth factorpromoted angiogenesis. FEBS Lett 2007, 581:1157-1160.
34. Walker VG, Li Z, Hulderman T, Schwegler-Berry D, Kashon ML, Simeonova PP: Potential in vitro effects of carbon nanotubes on human aortic endothelial cells. Toxicol Appl Pharmacol 2009, 236:319-328.
35. Chaudhuri P, Harfouche R, Soni S, Hentschel DM, Sengupta S: Shape effect of carbon nanovectors on angiogenesis. ACS Nano 2010, 4:574-582.
36. Prylutska SV, Burlaka AP, Prylutskyy YI, Ritter U, Scharff P: Pristine C(60) fullerenes inhibit the rate of tumor growth and metastasis. Exp Oncol 2011, 33:162-164.
37. Mroz P, Tegos GP, Gali H, Wharton T, Sarna T, Hamblin MR: Photodynamic therapy with fullerenes. Photochem Photobiol Sci 2007, 6:1139-1149.
38. Zogovic NS, Nikolic NS, Vranjes-Djuric SD, Harhaji LM, Vucicevic LM, Janjetovic KD, Misirkic MS, Todorovic-Markovic BM, Markovic ZM, Milonjic SK, Trajkovic VS: Opposite effects of nanocrystalline fullerene (C(60)) on tumour cell growth in vitro and in vivo and a possible role of immunosupression in the cancer-promoting activity of C(60). Biomaterials 2009, 30:6940-6946.
39. Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA, Geppetti P, Ledda F: Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 1994, 94:2036-2044.
40. Maulik N: Reactive oxygen species drives myocardial angiogenesis? Antioxid Redox Signal 2006, 8:2161-2168.
41. Harhaji L, Isakovic A, Raicevic N, Markovic Z, Todorovic-Markovic B, Nikolic N, Vranjes-Djuric S, Markovic I, Trajkovic V: Multiple mechanisms underlying the anticancer action of nanocrystalline fullerene. Eur J Pharmacol 2007, 568:89-98.
42. Sayes CM, Gobin AM, Ausman KD, Mendez J, West JL, Colvin VL: Nano-C60 cytotoxicity is due to lipid peroxidation. Biomaterials 2005, 26:7587-7595.
43. Ostendorf T, Van Roeyen C, Westenfeld R, Gawlik A, Kitahara M, De Heer E, Kerjaschki D, Floege J, Ketteler M: Inducible nitric oxide synthase-derived nitric oxide promotes glomerular angiogenesis via upregulation of vascular endothelial growth factor receptors. J Am Soc Nephrol 2004, 15:2307-2319.
44. Monti D, Moretti L, Salvioli S, Straface E, Malorni W, Pellicciari R, Schettini G, Bisaglia M, Pincelli C, Fumelli C, Bonafè M, Franceschi C: C60 carboxyfullerene exerts a protective activity against oxidative stressinduced apoptosis in human peripheral blood mononuclear cells. Biochem Biophys Res Commun 2000, 277:711-717.
45. Isakovic A, Markovic Z, Todorovic-Markovic B, Nikolic N, Vranjes-Djuric S, Mirkovic M, Dramicanin M, Harhaji L, Raicevic N, Nikolic Z, Trajkovic V: Distinct cytotoxic mechanism of pristine versus hydroxylated fullerene. Toxicol Sci 2006, 91:173-183.
46. Meng H, Xing G, Sun B, Zhao F, Lei H, Li W, Song Y, Chen Z, Yuan H, Wang X, Long J, Chen C, Liang X, Zhang N, Chai Z, Zhao Y: Potent angiogenesis inhibition by the particulate form of fullerene derivatives. ACS Nano 2010, 4:2773-2783.